652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
Arbour K, Punekar S, Garrido-Laguna I, Hong D, Wolpin B, Pelster M, Barve M, Starodub A, Sommerhalder D, Chang S, Zhang Y, Salman Z, Wang X, Gustafson C, Spira A. 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Annals Of Oncology 2023, 34: s458. DOI: 10.1016/j.annonc.2023.09.1838.Peer-Reviewed Original ResearchNon-small cell lung cancerPancreatic ductal adenocarcinomaPreliminary clinical activityKRAS mutant pancreatic ductal adenocarcinomaCell lung cancerFirst-in-classDuctal adenocarcinomaLung cancerRAS selectionAdenocarcinoma